Journal articles: 'Hokusai'

1

Mayor, A. Hyatt, and Yasuko Betchaku. "Hokusai." Metropolitan Museum of Art Bulletin 43, no. 1 (1985): 1. http://dx.doi.org/10.2307/3263896.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Behrens, Roy R. "Hokusai." Leonardo 39, no. 2 (April 2006): 170. http://dx.doi.org/10.1162/leon.2006.39.2.170.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Davis, Dick. "Haydn and Hokusai." Hudson Review 51, no. 3 (1998): 545. http://dx.doi.org/10.2307/3852721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Anía Ruiz-Flores, Pablo César. "Almazán Tomás, V. D., Hokusai Manga, 1 y Hokusai Manga, 2." Artigrama, no. 38 (June 27, 2024): 480–81. http://dx.doi.org/10.26754/ojs_artigrama/artigrama.20233810073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Tanaka, Hidemichi. "Sharaku Is Hokusai: On Warrior Prints and Shunro's (Hokusai's) Actor Prints." Artibus et Historiae 20, no. 39 (1999): 157. http://dx.doi.org/10.2307/1483579.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Matisoff, Susan, and Peter Morse. "Hokusai: One Hundred Poets." Monumenta Nipponica 45, no. 3 (1990): 367. http://dx.doi.org/10.2307/2384914.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Jenkins, Donald, Gian Carlo Calza, and John T. Carpenter. "Hokusai Paintings: Selected Essays." Monumenta Nipponica 50, no. 3 (1995): 423. http://dx.doi.org/10.2307/2385565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sandler, Mark H., and Gian Carlo Calza. "Hokusai Paintings: Selected Essays." Journal of Japanese Studies 22, no. 1 (1996): 159. http://dx.doi.org/10.2307/133056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

A, J. "Die Hokusai-Welle kommt." CardioVasc 13, no. 4 (September 2013): 15. http://dx.doi.org/10.1007/s15027-013-0158-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Steiner, Evgeny S. "Hokusai Manga: Contextualisation of Its Title and Genre." Observatory of Culture, no. 2 (April 28, 2014): 68–77. http://dx.doi.org/10.25281/2072-3156-2014-0-2-68-77.

Full text

Abstract:

Is devoted to Manga as the biggest and the bestknown work of Hokusai (北斎, 1760-1849). The paper discusses the phenomenon of Hokusai Manga and its place in the context of Japanese picture books. Was it a drawing manual or comic cartoons or perhaps a pictorial encyclopedia? What are the historical meanings and etymology of the word manga and its littleunderstood supraheading “Denshin Kaishu”?

APA, Harvard, Vancouver, ISO, and other styles

11

Carelli, Francesco. "Hokusai: beyond the Great Wave." London Journal of Primary Care 10, no. 4 (June 13, 2018): 128–29. http://dx.doi.org/10.1080/17571472.2018.1486504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Yglesias, Jorge. ""El último invierno de hokusai"." Chasqui 24, no. 1 (1995): 119. http://dx.doi.org/10.2307/29741206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

TEKDEMİR DÖKEROĞLU, Özlem. "HOKUSAİ ve SANATI ÜZERİNE GÖRSEL BİR OKUMA/A Visual Reading On Hokusai And Art." International Journal of Interdisciplinary and Intercultural Art 5, no. 5 (2018): 33–43. http://dx.doi.org/10.29228/ijiia.5.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Cartwright, Julyan H. E., and Hisami Nakamura. "What kind of a wave is Hokusai's Great wave off Kanagawa ?" Notes and Records of the Royal Society 63, no. 2 (February 25, 2009): 119–35. http://dx.doi.org/10.1098/rsnr.2007.0039.

Full text

Abstract:

The great wave off Kanagawa by Katsushika Hokusai is probably the most famous image in Japanese art. It depicts three boats in heavy seas on the point of encountering the eponymous wave, while Mount Fuji is glimpsed in the distance. The print is today often reproduced as the artistic depiction of a tsunami. Did Hokusai really have a tsunami in mind when he composed this work? We examine that hypothesis together with the alternatives, by discussing the image itself and the circumstances surrounding its composition, and by evaluating the wave in terms of the fluid dynamics of breaking waves and in particular of the species termed plunging breakers, of which The great wave is a member, and conclude that it is more probable that Hokusai intended to depict an exceptionally large storm wave. There is a great deal of scientific interest at present in such abnormally high waves, which are often termed freak or rogue waves.

APA, Harvard, Vancouver, ISO, and other styles

15

Anía Ruiz-Flores, Pablo César. "La presencia de Hokusai en la prensa española (1868-1912): biografía, obra y valoración crítica." Mirai. Estudios Japoneses 3 (August 6, 2019): 143–63. http://dx.doi.org/10.5209/mira.63110.

Full text

Abstract:

En el presente artículo se trata el impacto de Hokusai en España a través de las publicaciones periódicas en el último tercio del siglo XIX y primeras décadas del siglo XX coincidiendo con los periodos japoneses Meiji (1868-1912) y Taishō (1912-1926), época en la que el arte japonés y el fenómeno del japonismo se encontraban en pleno auge. El impacto de Hokusai en nuestro país a través de las publicaciones periódicas no fue tan importante como el que se produjo en otras naciones occidentales que tuvieron en esta época vínculos más estrechos con Japón y donde el coleccionismo de arte japonés (en especial de grabados ukiyo-e) fue más importante. No obstante, tanto en revistas ilustradas como en buena parte de los periódicos nacionales y locales de nuestro país se hicieron eco de la importancia de este destacado artista japonés proporcionando noticias sobre su vida y su obra, además de brindar informaciones sobre su influencia en otros artistas y sobre el coleccionismo de sus obras. De esta forma el conocimiento tanto de Hokusai como de su obra gozó de una notable difusión alcanzando todos los estratos de la sociedad y presentando un importante calado.

APA, Harvard, Vancouver, ISO, and other styles

16

Allen, Nancy S. "HOKUSAI. Matthi Forrer , Edmond de Goncourt." Art Documentation: Journal of the Art Libraries Society of North America 8, no. 2 (July 1989): 107–8. http://dx.doi.org/10.1086/adx.8.2.27948073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Dudley, J. M., V. Sarano, and F. Dias. "On Hokusai's Great wave off Kanagawa : localization, linearity and a rogue wave in sub-Antarctic waters." Notes and Records of the Royal Society 67, no. 2 (March 6, 2013): 159–64. http://dx.doi.org/10.1098/rsnr.2012.0066.

Full text

Abstract:

The Hokusai woodcut entitled The great wave off Kanagawa has been interpreted as an unusually large storm wave, likely to be classed as a rogue wave, and possibly generated from nonlinear wave dynamics (J. H. E. Cartwright and H. Nakamura, Notes Rec. R. Soc. 63 , 119–135 (2009)). In this paper, we present a complementary discussion of this hypothesis, discussing in particular how linear and nonlinear mechanisms can both contribute to the emergence of rogue wave events. By making reference to the Great wave 's simultaneous transverse and longitudinal localization, we show that the purely linear mechanism of directional focusing also predicts characteristics consistent with those of the Great wave . In addition, we discuss the properties of a particular rogue wave photographed on the open ocean in sub-Antarctic waters, which shows two-dimensional localization and breaking dynamics remarkably similar to Hokusai's depiction in the woodcut.

APA, Harvard, Vancouver, ISO, and other styles

18

Mills, Dillon. "Hokusai, Japanese Folklore, and Modern American Horror." Journal of Purdue Undergraduate Research 4, no. 1 (August 12, 2014): 92–93. http://dx.doi.org/10.5703/1288284315468.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Mahé, Isabelle, Ismaïl Elalamy, Grigoris T. Gerotziafas, and Philippe Girard. "Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI." TH Open 03, no. 03 (July 2019): e309-e315. http://dx.doi.org/10.1055/s-0039-1696659.

Full text

Abstract:

AbstractDirect oral anticoagulants (DOACs) represent an attractive alternative to low-molecular-weight heparins (LMWHs) for the long-term treatment of cancer-associated thrombosis (CT) since they avoid the burden of daily injections. Analyses in subgroups of cancer patients from large randomized trials suggested that DOACs were at least as effective as vitamin K antagonists, while indirect comparisons suggested that DOACs' efficacy and safety profile were comparable to those of LMWHs. In the randomized controlled HOKUSAI-VTE Cancer study, currently the only completed phase III trial on DOACs in CT patients, edoxaban was shown noninferior to dalteparin on the composite primary endpoint of time to first recurrent venous thromboembolism or major bleeding during the 12 months after randomization. Study results suggest that both agents had comparable benefit/risk ratio in patients with CT. Even though this conclusion was valid from a strict statistical viewpoint, it was potentially misleading when interpreting benefit/risk ratios. Besides the obvious heterogeneity of the study population (e.g., 23% of patients no longer had cancer) and significantly different treatment durations between arms, secondary outcomes for efficacy were in favor of edoxaban for recurrent deep-vein thrombosis but not for recurrent pulmonary embolism, and major bleeding episodes were significantly more frequent in the edoxaban group, with an excess of gastrointestinal (GI) bleeding episodes observed mainly but not only in patients with GI cancers. More research is needed regarding specific patients' profiles, cancer types, and treatment period to better clarify the respective roles of DOACs and LMWHs in CT patients.

APA, Harvard, Vancouver, ISO, and other styles

20

Bell, David. "Katsushika Hokusai and a Poetics of Nostalgia." Educational Philosophy and Theory 47, no. 6 (October 28, 2014): 579–95. http://dx.doi.org/10.1080/00131857.2014.964158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wright, Jack, David A. Rothery, Matthew R. Balme, and Susan J. Conway. "Geology of the Hokusai quadrangle (H05), Mercury." Journal of Maps 15, no. 2 (June 17, 2019): 509–20. http://dx.doi.org/10.1080/17445647.2019.1625821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Di Nisio, Marcello, Suzanne M. Bleker, Annelise Segers, Michele F. Mercuri, Lee Schwocho, Ajay Kakkar, Jeffrey I. Weitz, et al. "Edoxaban for treatment of venous thromboembolism in patients with cancer." Thrombosis and Haemostasis 114, no. 12 (2015): 1268–76. http://dx.doi.org/10.1160/th15-06-0452.

Full text

Abstract:

SummaryDirect oral anticoagulants may be effective and safe for treatment of venous thromboembolism (VTE) in cancer patients, but they have not been compared with low-molecular-weight heparin (LMWH), the current recommended treatment for these patients. The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer. We present the rationale and some design features of the study. One such feature is the composite primary outcome of recurrent VTE and major bleeding during a 12-month study period. These two complications occur frequently in cancer patients receiving anticoagulant treatment and have a significant impact. The evaluation beyond six months will fill the current gap in the evidence base for the long-term treatment of these patients. Based on the observation that the risk of recurrent VTE in patients with active cancer is similar to that in those with a history of cancer, the Hokusai VTE-cancer study will enrol patients if whose cancer was diagnosed within the past two years. In addition, patients with incidental VTE are eligible because their risk of recurrent VTE is similar to that in patients with symptomatic disease. The unique design features of the Hokusai VTE-cancer study should lead to enrolment of a broad spectrum of cancer patients with VTE who could benefit from oral anticoagulant treatment.

APA, Harvard, Vancouver, ISO, and other styles

23

Mahé, Isabelle, Ismaïl Elalamy, Grigoris T. Gerotziafas, and Philippe Girard. "Erratum: Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI." TH Open 03, no. 04 (October 2019): e348-e349. http://dx.doi.org/10.1055/s-0039-3400276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Zambiazi, Priscilla J., Gabriel de O. Aparecido, Thiago V. de B. Ferraz, William S. J. Skinner, Rafael G. Yoshimura, Daniel E. B. Moreira, Rafael L. Germscheidt, et al. "Electrocatalytic water oxidation reaction promoted by cobalt-Prussian blue and its thermal decomposition product under mild conditions." Dalton Transactions 49, no. 45 (2020): 16488–97. http://dx.doi.org/10.1039/d0dt02220a.

Full text

Abstract:

Water oxidation studies with Co-Prussian blue and Co₃O₄. Figure adapted from ‘Under the Wave off Kanagawa’ (Kanagawa oki nami ura), also known as ‘The Great Wave’, from the series ‘Thirty-six Views of Mount Fuji’ (‘Fugaku sanjūrokkei’) by K. Hokusai.

APA, Harvard, Vancouver, ISO, and other styles

25

Susanne, Krome. "Edoxaban ist Heparin nicht unterlegen." Onkologische Welt 09, no. 01 (February 2018): 32. http://dx.doi.org/10.1055/s-0038-1637776.

Full text

Abstract:

Für Patienten mit Tumorerkrankungen und venösem thromboembolischen Ereignis (VTE) empfehlen die Leitlinien für die Rezidivprophylaxe niedermolekulares Heparin. Über die langfristige Effektivität und Sicherheit direkter oraler Antikoagulanzien (DOAC) lagen bisher keine Untersuchungen vor. Die internationale HOKUSAI-Studie verglich deshalb Edoxaban und subkutanes Dalteparin bei Patienten mit Karzinom und thromboembolischer Komplikation.

APA, Harvard, Vancouver, ISO, and other styles

26

Hotta, Chizuko, and Setsuko Okano. "The Bon Festival of the Hokusai Area in Mie." Journal for the Integrated Study of Dietary Habits 9, no. 4 (1999): 64–68. http://dx.doi.org/10.2740/jisdh.9.4_64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bode, C., and I. Ahrens. "Oral anticoagulation with edoxaban." Hämostaseologie 32, no. 03 (2012): 212–15. http://dx.doi.org/10.5482/hamo-12-05-0004.

Full text

Abstract:

SummaryEdoxaban (the former DU176b) an orally available direct factor Xa inhibitor has been engineered from DX-9065a, which was one of the first parenteral Xa inhibitors. Edoxaban has a time to peak plasma concentrations of 1–2 hours and a half-life of approximately 10 hours after multiple doses. Edoxaban is the third new oral anticoagulant in the group of direct factor Xa inhibitors that has gained clinical approval for the prevention of venous thromboembolism after major orthopaedic surgery. Currently, edoxaban is assessed in late stage clinical development for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (ENGAGE AF-TIMI 48, NCT00781391) and for the treatment and prevention of venous thromboembolism in patients with acute deep vein thrombosis and/or pulmonary embolism (HOKUSAI VTE, NCT00986154).Both clinical phase III trials represent the largest single clinical studies in their entity so far with an enrolment of 21 107 patients in ENGAGE AF-TIMI 48 and a planned enrolment of 7500 patients in HOKUSAI VTE.The pharmacological properties of edoxaban will be discussed along with the current late stage clinical development focusing on the prevention of stroke and venous thromboembolism.

APA, Harvard, Vancouver, ISO, and other styles

28

Frere, Corinne, Benjamin Crichi, Manon Lejeune, Jean-Philippe Spano, and Nicolas Janus. "Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?" Cancers 12, no. 4 (April 9, 2020): 917. http://dx.doi.org/10.3390/cancers12040917.

Full text

Abstract:

Direct oral anticoagulants (DOAC) are now recommended for the treatment of cancer-associated thrombosis (CAT) based on the results of dedicated trials demonstrating that DOAC are non-inferior to low molecular weight heparins in preventing recurrent venous thromboembolism (VTE) in this population. The definition of “cancer patient” differs substantially among studies. Whether patients with active cancer and those with a history of cancer (HOC) carry the same risks of recurrent VTE and bleeding remains unclear. Few studies reported data on the efficacy and safety of anticoagulants according to active cancer or HOC categories. While in subgroup analyses of EINSTEIN and HOKUSAI the rates of recurrent VTE and bleeding did not differ between these categories, results from a subgroup analysis of AMPLIFY, from HOKUSAI-Cancer, and from the COMMAND cohort suggest that HOC patients might have a lower bleeding risk than active cancer patients. Whether the inclusion of HOC patients in CAT studies might introduce some bias by decreasing the rates of both recurrent VTE and bleeding remains an unanswered issue since no dedicated prospective study addressed this question. A strict definition of active cancer should be used in further trials.

APA, Harvard, Vancouver, ISO, and other styles

29

Kaliel, Hannah, Meghan Mior, Steven Quan, Sunita Ghosh, Cynthia Wu, and Tammy J. Bungard. "Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada." Clinical and Applied Thrombosis/Hemostasis 27 (January 1, 2021): 107602962097548. http://dx.doi.org/10.1177/1076029620975489.

Full text

Abstract:

Low molecular weight heparin (LMWH) is the standard of care for treating cancer-associated thrombosis (CAT), although new evidence for direct oral anticoagulants (DOACs) supports use in specific cancer populations. In this retrospective review at a specialty CAT clinic from 2016 to 2019, we report the use of anticoagulants (LMWH, DOACs, warfarin, anticoagulant class change) in the acute and chronic phases of CAT and compare use before/after publication of the Hokusai-VTE Cancer trial. Death, venous thromboembolism (VTE) recurrence and bleeding was also reported. Of the 221 included, median age was 69 years, with 57.5% having metastatic disease. In the acute phase, 80.1% were prescribed LMWH, 4.1% DOAC, and 14.5% had an anticoagulant class change (LMWH to DOAC; 78.1%). In the chronic phase, 35.8% were prescribed LMWH, 11.3% DOAC, and 42.9% had an anticoagulant class change (LMWH to DOAC; 90.1%). Use of DOACs in the acute and chronic phase prior to the Hokusai-VTE trial was 1.0% and 2.0%, respectively, and following publication was 6.8% and 19.6%. Death occurred for 22.6% patients, recurrent VTE in 7.2%, and bleeding in 5.0%. DOAC use is increasing with time; real-world data may help to guide optimization of the care of complex patients.

APA, Harvard, Vancouver, ISO, and other styles

30

TAYLOR, CHRIS. "HOKUSAI: FIRST MANGA MASTER BY JOCELYN BOUQUILLARD AND CHRISTOPHER MARQUET." Art Book 15, no. 1 (February 2008): 79. http://dx.doi.org/10.1111/j.1467-8357.2008.00932_8.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kadar, Endre E., and Judith A. Effken. "Paintings as Architectural Space: “Guided Tours” by Cézanne and Hokusai." Ecological Psychology 20, no. 4 (November 5, 2008): 299–327. http://dx.doi.org/10.1080/10407410802421874.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Coaldrake, William H. "Hokusai: One Hundred Views of Mt. Fuji. By Katsushika Hokusai. Introduction and commentaries by Henry D. Smith II. New York: George Braziller, 1988. $35.00." Journal of Asian Studies 48, no. 3 (August 1989): 618–19. http://dx.doi.org/10.2307/2058676.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Fedotkina, Yulia A. "HOW TO TREAT VTEC IN CANCER PATIENTS IN THE ACUTE PERIOD? EXTENDED TREATMENT. THE ROLE OF DIRECT ORAL ANTICOAGULANTS. THE RESULTS OF HOKUSAI VTE CANCER STUDY." Atherothrombosis Journal, no. 2 (December 27, 2018): 28–35. http://dx.doi.org/10.21518/2307-1109-2018-2-28-35.

Full text

Abstract:

Cancer is one of the most significant risk factors for venous thromboembolic complications (VTEC). The article discusses the features of the treatment of cancer patients with VTEC. The issues of alternative anticoagulant therapy are considered. The article presents the results of HOKUSAI VTE Cancer study, the first completed study to compare the efficacy and safety of a direct oral anticoagulant endoxaban with a low molecular weight heparin dalterapin for the treatment of VTEC in cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

34

Brekelmans, Marjolein, Suzanne Bleker, Rupert Bauersachs, Zoltan Boda, Harry Büller, Youngsook Choi, Alex Gallus, et al. "Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists." Thrombosis and Haemostasis 116, no. 07 (January 2016): 155–61. http://dx.doi.org/10.1160/th15-11-0892.

Full text

Abstract:

SummaryEdoxaban is a once-daily direct oral anticoagulant (DOAC). The Hokusai-VTE study revealed that, after initial treatment with heparin, edoxaban was non-inferior to and safer than vitamin K antagonists (VKA) in the prevention of recurrent deep-vein thrombosis and pulmonary embolism. This is the first report on the clinical relevance and management of bleeding events with edoxaban. All major bleeding events were classified blindly by three study-independent adjudicators. Predefined criteria were used to classify severity of clinical presentation and, separately, the clinical course and outcome into four categories. Major bleeding occurred in 56 patients treated with edoxaban and 65 patients treated with VKA. The severest categories (3 or 4) of the clinical presentation were assigned to 46 % of the major bleeding episodes in edoxaban recipients versus 58 % of the major bleeds in VKA recipients (odds ratio [OR] 0.62, 95 % confidence interval [CI] 0.30–1.27, p = 0.19). Clinical course was classified as severe (category 3 or 4) in 23 % of the edoxaban and 29 % of the VKA associated bleeds (OR 0.73, 95 % CI 0.32–1.66, p = 0.46). In conclusion, edoxaban associated major bleeding events have a comparable clinical presentation and course to major bleeds with VKA in patients treated for venous thromboembolism in the Hokusai-VTE study. These results may assure physicians that it is safe to prescribe this medication. If a major bleeding during edoxaban treatment occurs, its clinical presentation and clinical course are not worse than in VKA-treated patients.

APA, Harvard, Vancouver, ISO, and other styles

35

MARUYAMA, Shigenori. "Mt. Fuji between Two Great Waves by Katsushika Hokusai (1831-1833)." Journal of Geography (Chigaku Zasshi) 116, no. 1 (2007): Plate1—Plate2. http://dx.doi.org/10.5026/jgeography.116.plate1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Xiao, Zhiyong, Nils C. Prieur, and Stephanie C. Werner. "The self-secondary crater population of the Hokusai crater on Mercury." Geophysical Research Letters 43, no. 14 (July 28, 2016): 7424–32. http://dx.doi.org/10.1002/2016gl069868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Jordan, Brenda G. "Hokusai Paintings: Selected Essays. Edited by Glan Carlo Calza with the assistance of John T. Carpenter. Venice: The International Hokusai Research Centre, University of Venice, 1994. 319 pp." Journal of Asian Studies 55, no. 1 (February 1996): 164–65. http://dx.doi.org/10.2307/2943666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Brekelmans, Marjolein, Harry Büller, Michele Mercuri, Walter Ageno, Cathy Chen, Alexander Cohen, Nick van Es, et al. "Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent." TH Open 02, no. 01 (January 2018): e1-e7. http://dx.doi.org/10.1055/s-0037-1615251.

Full text

Abstract:

AbstractPulmonary embolism (PE) studies used direct oral anticoagulants (DOACs) with or without initial heparin. We aimed to (1) evaluate if PE patients benefit from initial heparin; (2) describe patient characteristics in the DOAC studies; and (3) investigate whether the anatomical extent of PE correlates with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, cause of PE, and recurrence rate. Our methods were (1) an indirect meta-analysis comparing the recurrence risk in DOAC-treated patients with or without initial heparin to those patients given heparin/vitamin K antagonist (VKA). (2) To compare the PE studies, information was extracted on baseline characteristics including anatomical extent. (3) The Hokusai-VTE study was used to correlate anatomical extent of PE with NT-proBNP levels, causes of PE, and recurrent venous thromboembolism (VTE). The meta-analysis included 11,539 PE patients. The relative risk of recurrent VTE with DOACs versus heparin/VKAs was 0.8 (95% confidence interval [CI]: 0.6–1.1) with heparin lead-in and 1.1 (95% CI: 0.8–1.5) without heparin. In the DOAC studies, the proportion of patients with extensive PE varied from 24 to 47%. In Hokusai-VTE, NT-proBNP was elevated in 4% of patients with limited and in over 60% of patients with extensive disease. Cause of PE and anatomical extent were not related. Recurrence rates increased from 1.6% with limited to 3.2% with extensive disease in heparin/edoxaban-treated patients, and from 2.4 to 3.9% in heparin/warfarin recipients. In conclusion, indirect evidence suggests a heparin lead-in before DOACs may be advantageous in PE. Anatomical extent was related to elevated NT-proBNP and outcome, but not to PE cause.

APA, Harvard, Vancouver, ISO, and other styles

39

Хрыщанович, В. Я. "Treatment of Cancer-Associated Venous thrombosis with Direct Oral Anticoagulants." Кардиология в Беларуси, no. 1 (April 7, 2020): 100–114. http://dx.doi.org/10.34883/pi.2020.12.1.009.

Full text

Abstract:

Стандартная антикоагулянтная терапия онко-ассоциированного венозного тромбоза (ОАТ) антагонистами витамина K может быть затруднена или невозможна вследствие осложнений геморрагического характера и лекарственных взаимодействий на фоне противоопухолевой химиотерапии, а также в результате низкой приверженности пациентов к лечению низкомолекулярными гепаринами (НМГ). Вполне логично предположить, что прямые оральные антикоагулянты (ПОАК) в определенной степени могли бы позволить преодолеть указанные проблемы, однако до недавнего времени отсутствовали крупные клинические исследования, посвященные оценке их эффективности и безопасности у онкологических пациентов. В настоящем обзоре обобщены выводы современных клинических руководств и рекомендаций, результаты последних рандомизированных контролируемых испытаний (SELECT-D, Hokusai-VTE Cancer, CARAVAGGIO, ADAM VTE), данные реальной клинической практики, связанные с применением ПОАК для лечения ОАТ. На основании изученного материала было сделано заключение о необходимости использования НМГ в терапии ОАТ на протяжении по меньшей мере 36 месяцев. Вместе с тем полученные сведения указали на высокую частоту отказа пациентов от лечения НМГ и бльшую приверженность к приему оральных антикоагулянтов, в том числе ПОАК. Исследование Hokusai-VTE Cancer продемонстрировало схожие суммарные показатели рецидива венозной тромбоэмболии (ВТЭ) и больших кровотечений в группах пациентов, получавших эдоксабан и дальтепарин (12,8 vs 13,5), в то время как наиболее высокий риск кровотечения на фоне приема эдоксабана был отмечен при гастроинтестинальном (ГИ) раке. Изучение ривароксабана в исследовании SELECT-D указало на меньшее количество рецидивов ВТЭ (4 vs 11), сопоставимый уровень больших кровотечений (6 vs 4) по сравнению с дальтепарином. Осложнения геморрагического характера наблюдались преимущественно при раке желудочно-кишечной и урогенитальной локализации наибольшее количество ривароксабан-ассоциированных больших кровотечений было у пациентов с опухолями пищевода и/или желудка (36 vs 11). Сравнительное исследование апиксабана/ дальтепарина (CARAVAGGIO) в настоящее время продолжается, а предварительные результаты проекта ADAM-VTE оказались весьма убедительными. Таким образом, ПОАК являются обоснованной альтернативой НМГ в лечении ОАТ. При ГИ раке назначение ПОАК следует рассматривать в каждом случае отдельно с учетом соотношения риск польза. Standard anticoagulant therapy of cancer-associated venous thrombosis (СAT) with vitamin K antagonists may be troublesome or impossible due to hemorrhagic complications and drug interactions on the background of antitumor chemotherapy and decreased patients adherence to treatment with low molecular weight heparins (LMWH). It is quite logical to assume that direct oral anticoagulants (DOAC) could resolve such problems to some extent however, until recently, there were no large clinical trials to assess their effectiveness and safety in cancer patients. This review summarizes the findings of modern clinical guidelines and recommendations, the obtained data of the latest randomized controlled trials (SELECT-D, Hokusai-VTE Cancer, CARAVAGGIO, ADAM VTE) and those of real clinical practice related to the use of DOAC for CAT treatment. On the base of the studied material, it was concluded that it is reasonable to use LMWH in CAT treatment for at least 36 months. At the same time, according to the obtained information, a high proportion of patients refused LMWH treatment and demonstrated their greater commitment to taking oral anticoagulants, including DOAC. The Hokusai-VTE Cancer Study showed similar overall rates of VTE recurrence and major bleedings in groups of patients treated with edoxaban and dalteparin (12.8 vs 13.5), while the highest risk of bleeding was noted in gastrointestinal (GI) cancer patients treated with edoxaban. Assessment of rivaroxaban in the SELECT-D study revealed fewer VTE relapses (4 vs 11), a similar level of major bleedings (6 vs 4) compared to dalteparin. Hemorrhagic complications were observed mainly in GI and urogenital cancer patients the largest number of rivaroxaban-associated major bleedings was in patients with tumors of the esophagus and/or stomach (36 vs 11). A comparative study of apixaban/dalteparin (CARAVAGGIO) is ongoing, but the preliminary results of the ADAM-VTE project turned out to be very convincing. Thus, DOAC is a reasonable alternative to LMWH in CAT treatment. In GI cancer, administration of DOACs should be considered in each case separately taking into account the risk-benefit ratio.

APA, Harvard, Vancouver, ISO, and other styles

40

van der Pol, Liselotte, Albert Mairuhu, Christophe Leroyer, Francis Couturaud, Menno Huisman, Frederikus Klok, and Cécile Tromeur. "Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice." Seminars in Interventional Radiology 35, no. 02 (June 2018): 83–91. http://dx.doi.org/10.1055/s-0038-1642622.

Full text

Abstract:

AbstractAnticoagulant therapy is the cornerstone of therapeutic management in acute venous thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis. Direct oral anticoagulants (DOACs) have become the standard of care because of their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs provided a similar efficacy and a better safety than conventional treatment with parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE therapeutic management. The results of published data from real-world registries confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.

APA, Harvard, Vancouver, ISO, and other styles

41

van Hout, Ben, Emma Hawe, and Alexander T. Cohen. "Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis." TH Open 04, no. 03 (July 2020): e245-e254. http://dx.doi.org/10.1055/s-0040-1716496.

Full text

Abstract:

Abstract Introduction In patients with venous thromboembolism (VTE), direct oral anticoagulants (DOACs) such as edoxaban, apixaban, dabigatran, and rivaroxaban are more convenient, safer, and just as effective as vitamin K antagonists (VKAs). Limited information is known about the effects of patient characteristics on VTE efficacy and safety of DOACs compared with VKAs, without appropriate effect modifier adjustment comparisons of DOACs may be biased. This study considers the effect of variables that can modify the efficacy and safety of edoxaban and warfarin, using patient-level data. Materials and Methods The primary efficacy and safety outcomes in the HOKUSAI-VTE study were VTE recurrence and clinically relevant bleeding, respectively. Potential effect modifiers were age, creatinine clearance, and weight. The relationship between the percentage of time in international normalized ratio (INR) control and outcomes were considered for the warfarin arm. Univariate and multivariate regression were performed for each patient characteristic. Results The relationship between treatment and VTE recurrence differed by age (interaction p = 0.007) and by creatinine clearance (p = 0.05). VTE recurrence differed by age for patients in the warfarin arm but not for those in the edoxaban arm and differed by INR control in the warfarin arm (p < 0.005). A stronger relationship between creatinine clearance and clinically relevant bleeding was found in the warfarin arm than in the edoxaban arm (p = 0.04). Clinically relevant bleeding differed by the percentage of time in INR control in the warfarin arm (p < 0.005). Age appeared to be a more important effect modifier than creatinine clearance in patients with VTE. Discussion The finding that efficacy in older patients was greater for those taking edoxaban than for those taking warfarin in the HOKUSAI-VTE study needs further investigation. Modification of the treatment effect by age for those taking warfarin might bias estimates of comparative effectiveness among DOACs if VKAs are the reference treatment.

APA, Harvard, Vancouver, ISO, and other styles

42

Ali, Assad, Nirja Shah, Raphael Bastianon Santiago, Mauricio Mandel, Michal Obrzut, Hamid Borghei-Razavi, Badih Adada, and Surabhi Ranjan. "INNV-27. SAFETY OF DIRECT ORAL ANTICOAGULANTS AS COMPARED TO LOW MOLECULAR WEIGHT HEPARIN IN TREATING VENOUS THROMBOEMBOLISM IN PATIENTS WITH PRIMARY BRAIN TUMORS AND BRAIN METASTASES." Neuro-Oncology 24, Supplement_7 (November 1, 2022): vii147. http://dx.doi.org/10.1093/neuonc/noac209.567.

Full text

Abstract:

Abstract INTRODUCTION Patients with brain tumors (PBTs) have a 20 to 30% incidence of venous thromboembolism (VTE) Recently, new direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran and edoxaban, have gained popularity in treating VTE in cancer patients due to ease of administration and favorable safety profile. DOACs are also being used in treating VTE in in PBTs. While clinical trials have established the safety of DOAC use in systemic cancers, there is only limited literature on safety of DOAC in PBTs. In this review, we explore all prospective and retrospective studies to evaluate the safety of DOAC in comparison to LMWH in treating VTEs in PBTs. METHODS A search on PubMed database using keywords “Direct Oral Anticoagulant,” OR “Oral Anticoagulant,” AND “Cancer,” AND “Clinical Trial” was performed for clinical trials. Another search using keywords “Direct Oral Anticoagulants,” OR “Oral Anticoagulant,” AND “Brain Tumor,” AND “Retrospective.” was performed for retrospective studies. RESULTS Of 359 clinical trials in cancer patients, only 4 evaluating DOAC versus LMWH, included PBTs– Hokusai, Select D, ADAM VTE and EINSTEIN-DVT/PE. Four retrospective studies (Lee 2021, Carney 2019, Schwartz 2021 and Leader 2021) were identified.These four clinical trials enrolled a very limited number of PBTs (0.7, 1.5%, 2.7% and 6.8% of all patients). The risk of ICH with DOAC as compared to LMWH was low in Hokusai trial (OR = 0.93; CI=0.14-5.9) and uninformative in other 3 trials (0 episodes of ICH in either/both groups). All four retrospective studies showed no increase in incidence of ICH in the DOAC versus LMWH group in PBTs. CONCLUSION In the small number of prospective and retrospective studies which have evaluated the safety of DOAC in comparison to LMWH in brain tumors, the use of DOAC appears to be safe with no increase in the risk of ICH over LMWH.

APA, Harvard, Vancouver, ISO, and other styles

43

KATO, Chika, and Shoichi OTA. "An Analysis on the Composition of the Great Wave at Kanagawa by Hokusai." Journal of Graphic Science of Japan 41, no. 4 (2007): 3–8. http://dx.doi.org/10.5989/jsgs.41.4_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Mulvey, Laura. "A Sudden Gust of Wind (after Hokusai): from After to Before the Photograph." Oxford Art Journal 30, no. 1 (March 1, 2007): 27–37. http://dx.doi.org/10.1093/oxartj/kcl030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ernst, Carolyn M., Nancy L. Chabot, and Olivier S. Barnouin. "Examining the Potential Contribution of the Hokusai Impact to Water Ice on Mercury." Journal of Geophysical Research: Planets 123, no. 10 (October 2018): 2628–46. http://dx.doi.org/10.1029/2018je005552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Katasonova, Elena. "Not Just Hokusai: Three Waves of Japanese Culture in the West. Part I." Oriental Courier, no. 3 (2023): 222. http://dx.doi.org/10.18254/s268684310028144-6.

Full text

Abstract:

For more than a century and a half, the fashion for Japanese art has been one of the most important trends in Western culture. The famous engraving by Katsushika Hokusai “The Great Wave in Kanagawa” (1830–1832) from the famous series “Thirty-Six Views of Mount Fuji” became its peculiar symbol. But how could it happen that this drawing, created by a Japanese artist for his own compatriots many years ago, sunk so deeply into the souls of Europeans? There are several answers to this question, and one of them boils down to the fact that the waves depicted in the engraving represent the opening of Japan to the outside world, from which the country was separated for more than two centuries (1641–1853).

APA, Harvard, Vancouver, ISO, and other styles

47

Saito, Tatsuya. "Critical Reactions to the 1890 Japanese Print Exhibition in Paris." Journal of Japonisme 2, no. 1 (January 18, 2017): 38–72. http://dx.doi.org/10.1163/24054992-00021p02.

Full text

Abstract:

The great Japanese pictorial arts retrospective held in Paris in 1890 drew considerable attention from critics. By examining press reviews, this article aims to clarify how the critics responded to the exhibition and Japanese prints. Many reviewers expressed favorable opinions of the exhibition, describing the characteristics of Japanese art and notable painters such as Hokusai, Hiroshige, and Utamaro as well as the so-called “primitive artists.” However, there was also harsh criticism of Japonisme and Japanese art, which is discussed here as well. Writers such as Teodor de Wyzewa, Edmond Pottier, and Jacques Tasset published original studies on the Japanese pictorial arts. Their writings will likewise be analyzed in order to present the wide variety of reactions in the critical sphere.

APA, Harvard, Vancouver, ISO, and other styles

48

Xiang, Wei. "Shaka Goichidaiki Zue: Vernacularization and Visualization of Buddha’s Biography in Nineteenth-Century Japan." Religions 15, no. 1 (January 12, 2024): 99. http://dx.doi.org/10.3390/rel15010099.

Full text

Abstract:

Since the appearance of Buddha, texts and images depicting his life have circulated across Eurasia, serving as significant mediums for disseminating Buddhist ideology. Japan has historically been influenced by the canon of Chinese Buddhism while concurrently striving to promote the indigenization of Buddhism. This endeavor reached its peak during the Edo period, notably exemplified in the Shaka goichidaiki zue, illustrated by the world-renowned artist Hokusai Katsushika. Originating from Buddhist believers, it presents an adaptation based on the socio-historical context of pre-modern Japan, particularly manifesting evident shifts in emphasizing royal authority, the salvation of females, and ethical relationships. Entering the Meiji era, this pre-modern illustrated manuscript underwent repeated printing, playing an important role in the modernization of Buddhism.

APA, Harvard, Vancouver, ISO, and other styles

49

Bossaer, John B., and Kelly L. Covert. "Direct oral anticoagulants in patients with cancer." American Journal of Health-System Pharmacy 76, no. 14 (July 2, 2019): 1019–27. http://dx.doi.org/10.1093/ajhp/zxz095.

Full text

Abstract:

AbstractPurposeThis review summarizes the available evidence concerning direct oral anticoagulant (DOAC) use to treat venous thromboembolism (VTE) in patients with cancer as well as pertinent safety data on the use of DOACs in patients with both cancer and atrial fibrillation.SummaryThe introduction of DOACs into clinical practice changed the way thrombotic complications are managed and prevented in diverse patient populations, including VTE and atrial fibrillation. Low-molecular-weight heparins have been the standard of care for treating VTE in cancer patients due to superiority over vitamin K antagonists in preventing recurrent VTE. Therefore, widespread DOAC use for VTE in patients with active cancer has not been adopted.ConclusionRecent randomized clinical trials (SELECT-D, Hokusai VTE Cancer) have provided evidence that DOACs may have a role in treating VTE in cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

50

Wright, Jack, Paul K. Byrne, and David A. Rothery. "Planet Mercury: Volcanism in a theatre of global contraction, with examples from the Hokusai quadrangle." Journal of Volcanology and Geothermal Research 417 (September 2021): 107300. http://dx.doi.org/10.1016/j.jvolgeores.2021.107300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Hokusai'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles